$STX

Arumugavelu Shankar sold $928K of STX

Arumugavelu Shankar sold 1,000 shares of Seagate Technology Holdings plc (STX) at $927.68 ($0.93M total) on 2026-06-04.

Original reporting
SEC EDGAR · Arumugavelu Shankar
Published Jun 4, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

This disclosure updates the insider-activity tape for STX; traders may briefly reprice sentiment but should avoid treating it as a fundamental downgrade without corroborating news.

02

Market read

A same-day insider sale can create short-lived negative sentiment, but the transaction is small and lacks a stated fundamental catalyst.

03

What to watch

No 10b5-1 plan is cited, but the sale size is small and does not indicate a broader change in insider ownership trends.

Relevance 6/10Novelty 6/10Timing: Filed on 2026-06-04 (same day as sale disclosure)

Background

SEC Form 4 reports insider transactions (director/officer/10% owners) in the issuer’s own shares.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

Seagate director Arumugavelu Shankar sold $927.68/share worth $927,680 in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless followed by additional insider activity or fundamentals.

Evidence & confidence

The filing is a routine insider transaction with only 1,000 shares sold; it provides a datapoint on insider behavior but no new company-specific operational or financial catalyst.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A single small director sale may reflect diversification or liquidity needs rather than bearish expectations.

Key entities

  • Seagate Technology Holdings plc

    STX; director Arumugavelu Shankar reported an open-market sale of 1,000 shares.

  • Arumugavelu Shankar

    Director who sold 1,000 STX shares at $927.6800 on 2026-06-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.